Combined collagen membrane and hydroxyapatite/collagen chondroitin-sulfate spacer placement in the treatment of 2-wall intrabony defects in chronic adult and rapidly progressive periodontitis patients.
This study, confined to non-smokers, evaluated guided-tissue regeneration in deep 2-wall intrabony defects using a diphenylphosphorylazide-cross-linked bovine type I collagen membrane supported by a hydroxyapatite/collagen/chondroitin-sulfate spacer in 43 adult periodontitis (AP) and 14 rapidly progressive periodontitis (RPP) patients, no more than 1 defect being randomly selected for each patient. Before surgery and 6 months after surgery, plaque (PI) and sulcus bleeding (SBI) indices, probing pocket depths (PPD), gingival margin locations (GML) and probing attachment levels (PAL) were recorded. During the post-surgical period, the biomaterials were well tolerated in all patients and PI and SBI were kept at a low level. Following therapy, there was a significant gain in PAL (4.2 mm for AP; 3 mm for RPP) and reduction in PPD (6.1 mm for AP; 4.7 mm for RPP) for both groups of patients (p < 0.05). A significantly greater gain in PAL and reduction in PPD were observed for AP compared to RPP patients (p < 0.05). The change in GML was not statistically different between groups (1.8 mm for AP; 1.6 mm for RPP). It is concluded that the combined use of a diphenylphosphorylazide-cross-linked bovine type-I collagen membrane, supported by a hydroxyapatite/collagen/chondroitin-sulfate spacer, is beneficial in improving PAL and reducing PPD in 2-wall intrabony defects in both AP and RPP patients during the quiescent phase of the disease, with statistically better results for the former group. However, longer observation periods are necessary to evaluate the stability of the improvements obtained by this combined treatment approach between and for each group of patients.
Benqué
E
E
Department of Dental Medicine, Sart Tilman University Hospital, University of Liège, Belgium.
Zahedi
S
S
Brocard
D
D
Oscaby
F
F
Justumus
P
P
Brunel
G
G
D000328:Adult; D016301:Alveolar Bone Loss / Q000601:surgery*; D000818:Animals; D001386:Azides / Q000737:chemistry; D001672:Biocompatible Materials / Q000737:chemistry / Q000627:therapeutic use*; D002417:Cattle; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003094:Collagen / Q000737:chemistry / Q000627:therapeutic use*; D003432:Cross-Linking Reagents / Q000737:chemistry; D003774:Dental Plaque Index; D017886:Durapatite / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D005881:Gingiva / Q000473:pathology; D005884:Gingival Hemorrhage / Q000473:pathology; D005889:Gingival Recession / Q000473:pathology / Q000601:surgery; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods; D006801:Humans; D008137:Longitudinal Studies; D008567:Membranes, Artificial; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000473:pathology / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000473:pathology / Q000601:surgery; D010518:Periodontitis / Q000601:surgery*; D019736:Prostheses and Implants; D016896:Treatment Outcome
D001386:Azides; D001672:Biocompatible Materials; D003432:Cross-Linking Reagents; D008567:Membranes, Artificial; D002809:Chondroitin Sulfates; D003094:Collagen; D017886:Durapatite; C007523:diphenylphosphorazidate